According to the Xingqi Pharmaceutical announcement, the company received the SQ-23082 eye drops “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials. This drug is an improved chemical class 2.1 drug developed by the company. It is intended to be used to treat itchy eyes related to allergic conjunctivitis. Currently, no ophthalmic preparation products are on the market at home or abroad. Subsequent companies must carry out clinical research according to approval documents, and can only go public after approval by the State Drug Administration. There is uncertainty about the progress and results of clinical trials.

According to the Xingqi Pharmaceutical announcement, the company received the SQ-23082 eye drops “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials. This drug is an improved chemical class 2.1 drug developed by the company. It is intended to be used to treat itchy eyes related to allergic conjunctivitis. Currently, no ophthalmic preparation products are on the market at home or abroad. Subsequent companies must carry out clinical research according to approval documents, and can only go public after approval by the State Drug Administration. There is uncertainty about the progress and results of clinical trials.